Antibody–drug conjugates (ADCs) are becoming increasingly prominent in the oncology landscape. Eleven ADCs are marketed worldwide for haematological and solid tumour malignancies, of which six have gained regulatory approval since 2019. Most ADCs comprise a cytotoxic agent attached to a monoclonal antibody (mAb) that targets a specific tumour-associated antigen. This approach combines the targeted delivery of the mAb with the tumour-killing potential of the payload, which is generally too toxic to be systemically administered.

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD